3 May 2023
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Issue of Equity
Total Voting Rights
Ondine Biomedical Inc. (AIM: OBI) announces the issue of 390,550 common shares in the Company (the "Consideration Shares") to Hylife pursuant to the services agreement entered into on 15 December 2020 ("Hylife Service Agreement"). Further details of the services provided under the Hylife Service Agreement are included in the Company's Admission Document dated 1 December 2021.
In accordance with the Hylife Service Agreement, the Consideration Shares are being issued at a price of $1.53421 USD per Consideration Share.
Admission and Total Voting Rights
Application is being made for the admission to trading on AIM ("Admission") of the 390,550 Consideration Shares, which will rank pari passu in all respects with the Company's existing common shares. Admission of the Consideration Shares is expected to become effective on 5 May 2023.
Following Admission, the total number of common shares in the Company with voting rights will be 194,983,407. The Company does not hold any shares in Treasury. The above figure of 194,983,407 common shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
| Ondine Biomedical Inc. |
|
| Angelika Vance, Corporate Communications | +001 (1) 604 838 2702 |
|
|
|
| Singer Capital Markets (Nominated Adviser and Joint Broker) |
|
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
|
|
|
| RBC Capital Markets (Joint Broker) |
|
| Rupert Walford, Kathryn Deegan | +44 (0) 20 7653 4000 |
|
|
|
| Vane Percy & Roberts (Media Contact) |
|
| Simon Vane Percy, Amanda Bernard | +44 (0) 77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave™. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.